Navigation Links
OncoGenex Pharmaceuticals Files Shelf Registration Statement
Date:6/26/2009

cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed the Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.

OGX-011, OGX-427 and OGX-225 utilize second-generation antisense technology, licensed from Isis Pharmaceuticals (NASDAQ: ISIS), to effectively target and inhibit production of specific proteins in tumor cells. OncoGenex and Isis partnered in the successful discovery of OGX-011, OGX-427 and OGX-225 and with respect to OGX-011, in its initial development. In 2008, OncoGenex and Isis amended their OGX-011 agreement to provide OncoGenex with sole rights to OGX-011 and sole responsibility for development and related costs and partnering decisions, subject to financial obligations to Isis. OncoGenex is also solely responsible for development and related costs and partnering decisions regarding OGX-427 and OGX-225. Key intellectual property related to OGX-011, OGX-427 and OGX-225 were discovered by the University of British Columbia and the Vancouver Prostate Centre, and were exclusively licensed to OncoGenex.

More information about OncoGenex is available at www.oncogenex.com.

This press release contains forward-looking statements and 'forward-looking information' within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws, including statements concerning the shelf registration statement, the timing of any offerings under the shelf registration statement, the use of proceeds of any potential offerings of securities under the shelf registration statement, potential partnering of OGX-011, anticipated clinical development activities and t
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
2. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
3. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
4. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
5. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
6. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
7. OncoGenex Reports First Quarter Financial Results
8. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
9. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
10. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
11. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2014)... 2014 Canada Endoscopy Visualization Systems ... on the Canada Endoscopy Visualization Systems market. The ... volume (in units) and average prices (in US ... Systems, Mid-Range Endoscopy Visualization Systems and Low-End Endoscopy ... http://www.marketresearchreports.biz/analysis/213254 . , The report also provides company ...
(Date:7/25/2014)... 26, 2014 "Ischemic Stroke and ... provides data on the Ischemic Stroke and Cerebral ... information and data relating to the clinical trials ... full global Ischemic Stroke Research Report 2014 at: ... of the trial numbers and their recruitment status ...
(Date:7/25/2014)... , July 25, 2014 Amgen (NASDAQ: ... today declared a $0.61 per share dividend for the ... on Sept. 5, 2014, to all stockholders of record ... 2014.  About Amgen Amgen is committed ... from serious illnesses by discovering, developing, manufacturing and delivering ...
(Date:7/25/2014)... -- Trillions of bacteria live in each person,s digestive ... digest food and stave off harmful infections, but their ... To help shed light on the role of these ... professor Eric Alm recently tracked fluctuations in the bacterial ... The findings, described in the July 25 issue of ...
Breaking Biology Technology:Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 3Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 5Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3Monitoring the rise and fall of the microbiome 2Monitoring the rise and fall of the microbiome 3
... Educational program offers unique resources to empower transplant patients ... ... Oct. 17 Astellas Pharma US,Inc. (Pink Sheets: ALPMF), a ... Society (ITNS), a leading transplant,professional organization, announced a collaborative partnership ...
... to Dominate the Type 2 Diabetes Market, According to a ... New Report from Decision Resources, ... have released a new report finding that Merck,will obtain blockbuster antidiabetic ... uptake of their DPP-IV inhibitor, Januvia.,Januvia will see rapid uptake as ...
... 24, at 1:30 p.m. EDT, ALAMEDA, Calif., ... a biopharmaceutical company developing innovative therapies,for the treatment ... to discuss third quarter results on Wednesday, October ... Kenneth Chahine, Chief Executive,Officer, and Michael Coffee, Chief ...
Cached Biology Technology:Astellas Pharma US, Inc. and The International Transplant Nurses Society (ITNS) Collaborate on Content for Transplant Experience Program 2Astellas Pharma US, Inc. and The International Transplant Nurses Society (ITNS) Collaborate on Content for Transplant Experience Program 3Merck Will Obtain Blockbuster Antidiabetic Drug Sales in Type 2 Diabetes Market by 2011 2Merck Will Obtain Blockbuster Antidiabetic Drug Sales in Type 2 Diabetes Market by 2011 3Avigen, Inc. Announces Third Quarter 2007 Earnings Conference Call 2
(Date:7/25/2014)... N.Y., July 25, 2014 In the first broad-scale estimate ... Service scientists and collaborators calculated that trees are saving ... 670,000 incidences of acute respiratory symptoms. , While trees, ... of less than 1 percent, the impacts of that ... of the reduced air pollution at nearly $7 billion ...
(Date:7/25/2014)... 100,000s of people lived on the land now called ... control the availability of plants they used for food, ... fire to maintain desired habitat and natural resources. , ... Pacific Southwest Station, will lead a field trip ... the Ecological Society of America,s 99th Annual Meeting, in ...
(Date:7/25/2014)... this false-color image from the Terra satellite show the different ... wildfires in Eastern Russia. The burn scars show up ... The wildfires have broken across the remote parts of Eastern ... image from the MODIS instrument, it is still possible ... Two recent image features noted below show the devastating number ...
Breaking Biology News(10 mins):First national study finds trees saving lives, reducing respiratory problems 2Fire ecology manipulation by California native cultures 2Fire ecology manipulation by California native cultures 3
... 2012) Eye injuries in war have changed ... tactics, technology and strategies have evolved. Today,s soldiers ... areas not protected by body armor. Military experts and ... and Ear will convene in Boston, Mass., on Sept. ...
... almost $19 million will help to develop technologies ... the National Human Genome Research Institute (NHGRI), part ... During the past decade, DNA sequencing costs ... technologies and process improvements developed by genomics researchers. ...
... time this morning getting your shoes on or thinking about ... suffering with debilitating diseases such as ALS (Lou Gehrig,s disease) ... breathing and eating -- can be a struggle. They ... hopes to help through research that has just been funded ...
Cached Biology News:New NIH/NHGRI grants to harness nanoscale technologies to cut DNA sequencing costs 2New NIH/NHGRI grants to harness nanoscale technologies to cut DNA sequencing costs 3Neurobiologist Rodal wins New Innovator award 2
200 μg per ml DNA in 10 SSPE, 2 Denhardt's...
... Reacts with an early ... infection 3 hours post-infection exhibiting ... reaches peak intensity between 6-24 ... extremely intense coarsely granular staining. ...
... clone 8G8/5 GenBank Accession Number : ... AP-2alpha/gamma fusion protein corresponding to residues 166-223 ... human AP-2γ Formulation: 0.1M Tris-glycine, pH 7.4, ... addition of glycerol to 30% Quality Assurance: ...
Parathyroid Hormone Receptor 2 [PTHR2]...
Biology Products: